Qingwei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingwei Chen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Dazhi Ke
Department of General practice, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 shared publicationsLi Wang
Department of General Practice, The Second Affiliated Hospital of Chongqing Medical University, No. 76 Linjiang Road, Chongqing, 400010, China
4 shared publicationsQiaoyun Yang
Department of General practice, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 shared publicationsGuiqiong Li
Department of Geriatrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
3 shared publications- Yipin Zhao
Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases), Central China Fuwai Hospital of Zhengzhou University, Henan Provincial Cardiovascular Hospital, Zhengzhou, Henan, People’s Republic of China
3 shared publications Chun-Qiu Li
Department of General practice, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications
Latest Publications
- Open Access
Multi-Omics Identifies Associations of Gut Roseburia Abundance and Butyrate Levels with Antiviral Responses to Entecavir Plus Interferon-α in HBV Mouse Models
Background: Individuals with chronic hepatitis B virus (HBV) infection present with gut dysbiosis. Evidence suggests that gut microbiota can affect the efficacy of anti-HBV therapy. However, limited research has comprehensively explored how gut microbiota and its related metabolites interact with HBV treatment response after antiviral treatment. Our study aims to identify an association between the dominant microbial cluster and HBV treatment response during anti-viral therapies. Methods: HBV carrier mice were utilized to assess the antiviral efficacy and peripheral and intrahepatic immune responses of entecavir (ETV) and ETV plus interferon-α (EI) therapies. We analyzed the gut microbiome, metabolome, and non-parenchymal hepatic cells transcriptome to determine the role of gut microbes and related metabolites in virological and intrahepatic immune responses to ETV and EI. Mice receiving no therapy (HBV control), ETV monotherapy, and EI therapy were used for comparison. Furthermore, we used immune cells to evaluate the effects of metabolites produced by the identified bacteria. Results: EI therapy showed a greater trend toward reducing serum HBsAg and HBeAg levels compared with ETV monotherapy, and significantly decreased intrahepatic HBcAg expression. Principal coordinates analysis revealed that gut microbes and metabolites were significantly different in the EI treatment group and the ETV and HBV groups. Notably, the relative abundance of short-chain fatty acid-producing bacteria was higher in the EI group, particularly in gut Roseburia abundance and butyrate levels. Butyrate levels were also elevated in the liver. However, whether this reflects intestinal absorption or hepatic synthesis remains undetermined. Butyrate is a potent inhibitor of histone deacetylases (HDACs), which can reduce the expression of hepatic HDAC and also suppress its activity. Hepatic HDAC1 protein levels were lower in the EI group than ETV group, consistent with the possibility that butyrate may modulate HDAC1 expression. Furthermore, EI treatment increased hepatic NKG2D+ NK cells and upregulated the NK cell-mediated cytotoxicity pathway. In vitro studies revealed that 0.5 mM butyrate enhanced the cytokine response of CD8+ T cells to HBV surface-specific antigens. Conclusions: Our multi-omics analysis reveals an association of gut Roseburia abundance and butyrate levels with improved virological responses to EI therapy. In vitro, butyrate enhanced the cytokine response of HBV-specific CD8+ T cells, suggesting a hypothesis that butyrate (but does not verify mediation of the virological responses to EI) may contribute to the antiviral response. While our multi-omics and in vitro data support a testable working hypothesis that butyrate may contribute to intrahepatic immune modulation, we acknowledge that causality is not established by this study. These results provide potential possibilities for future functional investigations of butyrate-producing microbiota as an adjunct to anti-HBV therapy.
Open AccessMulti-Omics Identifies Associations of Gut Roseburia Abundance and Butyrate Levels with Antiviral Responses to Entecavir Plus Interferon-α in HBV Mouse Models
Background: Individuals with chronic hepatitis B virus (HBV) infection present with gut dysbiosis. Evidence suggests that gut microbiota can affect the efficacy of anti-HBV therapy. However, limited research has comprehensively explored how gut microbiota and its related metabolites interact with HBV treatment response after antiviral treatment. Our study aims to identify an association between the dominant microbial cluster and HBV treatment response during anti-viral therapies. Methods: HBV carrier mice were utilized to assess the antiviral efficacy and peripheral and intrahepatic immune responses of entecavir (ETV) and ETV plus interferon-α (EI) therapies. We analyzed the gut microbiome, metabolome, and non-parenchymal hepatic cells transcriptome to determine the role of gut microbes and related metabolites in virological and intrahepatic immune responses to ETV and EI. Mice receiving no therapy (HBV control), ETV monotherapy, and EI therapy were used for comparison. Furthermore, we used immune cells to evaluate the effects of metabolites produced by the identified bacteria. Results: EI therapy showed a greater trend toward reducing serum HBsAg and HBeAg levels compared with ETV monotherapy, and significantly decreased intrahepatic HBcAg expression. Principal coordinates analysis revealed that gut microbes and metabolites were significantly different in the EI treatment group and the ETV and HBV groups. Notably, the relative abundance of short-chain fatty acid-producing bacteria was higher in the EI group, particularly in gut Roseburia abundance and butyrate levels. Butyrate levels were also elevated in the liver. However, whether this reflects intestinal absorption or hepatic synthesis remains undetermined. Butyrate is a potent inhibitor of histone deacetylases (HDACs), which can reduce the expression of hepatic HDAC and also suppress its activity. Hepatic HDAC1 protein levels were lower in the EI group than ETV group, consistent with the possibility that butyrate may modulate HDAC1 expression. Furthermore, EI treatment increased hepatic NKG2D+ NK cells and upregulated the NK cell-mediated cytotoxicity pathway. In vitro studies revealed that 0.5 mM butyrate enhanced the cytokine response of CD8+ T cells to HBV surface-specific antigens. Conclusions: Our multi-omics analysis reveals an association of gut Roseburia abundance and butyrate levels with improved virological responses to EI therapy. In vitro, butyrate enhanced the cytokine response of HBV-specific CD8+ T cells, suggesting a hypothesis that butyrate (but does not verify mediation of the virological responses to EI) may contribute to the antiviral response. While our multi-omics and in vitro data support a testable working hypothesis that butyrate may contribute to intrahepatic immune modulation, we acknowledge that causality is not established by this study. These results provide potential possibilities for future functional investigations of butyrate-producing microbiota as an adjunct to anti-HBV therapy.
- Open Access
- 2 April 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 309-321
The Global Burden of Chronic Kidney Disease Attributable to Hypertension in Young Adults From 1990 to 2021 and Projections to 2050
Chronic kidney disease (CKD) attributable to hypertension represents a major global public health challenge. This study evaluates the global burden of CKD statistically attributable to high systolic blood pressure (SBP), with a focus on young adults aged 25-49 years. To analyze trends in mortality and disability-adjusted life years (DALYs) attributable to high SBP among individuals with CKD aged 25-49 years from 1990 to 2021 and to project the future attributable burden through 2050. Observational study. Data were obtained from the Global Burden of Disease Study 2021. The analysis estimated the burden of CKD attributable to high SBP using a comparative risk assessment framework. Temporal trends were quantified using the estimated annual percentage change (EAPC). The association between attributable burden and the sociodemographic index (SDI) was also examined. Projections to 2050 were generated using autoregressive integrated moving average models. From 1990 to 2021, global mortality and DALY rates for CKD attributable to high SBP among young adults increased significantly (mortality EAPC, 1.75%; DALYs EAPC, 1.6%). The attributable burden remained consistently higher in males and increased with age, peaking in the 45-49-year age group. Overall, low- and low-middle-SDI regions experienced the greatest relative increases, although substantial heterogeneity was observed within SDI strata. At the national level, Ukraine showed the largest increase in mortality rate (EAPC, 13.21%), whereas the Republic of Korea exhibited the largest decline (EAPC, -4.68%). Model-based projections suggest a continued increase in both attributable mortality and DALYs through 2050, with persistent disparities by sex, age, and geographic region. The burden of CKD attributable to high SBP among young adults has increased substantially over the past three decades and is projected to rise further, reflecting persistent global inequalities. These findings highlight the urgent need for strengthened and targeted strategies for hypertension prevention and management in younger populations worldwide.
- 2 April 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 309-321
Open AccessThe Global Burden of Chronic Kidney Disease Attributable to Hypertension in Young Adults From 1990 to 2021 and Projections to 2050
Chronic kidney disease (CKD) attributable to hypertension represents a major global public health challenge. This study evaluates the global burden of CKD statistically attributable to high systolic blood pressure (SBP), with a focus on young adults aged 25-49 years. To analyze trends in mortality and disability-adjusted life years (DALYs) attributable to high SBP among individuals with CKD aged 25-49 years from 1990 to 2021 and to project the future attributable burden through 2050. Observational study. Data were obtained from the Global Burden of Disease Study 2021. The analysis estimated the burden of CKD attributable to high SBP using a comparative risk assessment framework. Temporal trends were quantified using the estimated annual percentage change (EAPC). The association between attributable burden and the sociodemographic index (SDI) was also examined. Projections to 2050 were generated using autoregressive integrated moving average models. From 1990 to 2021, global mortality and DALY rates for CKD attributable to high SBP among young adults increased significantly (mortality EAPC, 1.75%; DALYs EAPC, 1.6%). The attributable burden remained consistently higher in males and increased with age, peaking in the 45-49-year age group. Overall, low- and low-middle-SDI regions experienced the greatest relative increases, although substantial heterogeneity was observed within SDI strata. At the national level, Ukraine showed the largest increase in mortality rate (EAPC, 13.21%), whereas the Republic of Korea exhibited the largest decline (EAPC, -4.68%). Model-based projections suggest a continued increase in both attributable mortality and DALYs through 2050, with persistent disparities by sex, age, and geographic region. The burden of CKD attributable to high SBP among young adults has increased substantially over the past three decades and is projected to rise further, reflecting persistent global inequalities. These findings highlight the urgent need for strengthened and targeted strategies for hypertension prevention and management in younger populations worldwide.
- Open Access
- 27 November 2025
- Published by Springer Nature in Biology Direct
- Vol. 20 (1) , 113
NAMPT modulates muscle fiber type transition in PAD myopathy via the cGMP-PKG signaling pathway
Peripheral artery disease (PAD), caused by atherosclerosis resulting in reduced blood flow in the lower extremities, impairs both skeletal muscle mass and
- 27 November 2025
- Published by Springer Nature in Biology Direct
- Vol. 20 (1) , 113
Open AccessNAMPT modulates muscle fiber type transition in PAD myopathy via the cGMP-PKG signaling pathway
Peripheral artery disease (PAD), caused by atherosclerosis resulting in reduced blood flow in the lower extremities, impairs both skeletal muscle mass and
- Open Access
- 30 November 2023
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 21 (1) , 1-23
Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells
Atherosclerosis, a chronic inflammatory disease characterized by arterial plaque formation, is one of the most prominent causes of cardiovascular diseases. However, the current treatments often do not adequately compromise the chronic inflammation-mediated plaque accumulation and the disease progression. Therefore, a new and effective strategy that blocks atherosclerosis-associated inflammation is urgently needed to further reduce the risk. Colchicine, a potent anti-inflammatory medication, has shown great potential in the treatment of atherosclerosis, but its adverse effects have hampered its clinical application. Herein, we developed a novel delivery nanosystem encapsulated with colchicine (VHPK-PLGA@COL), which exhibited improved biosafety and sustained drug release along with the gradual degradation of PLGA and PEG as confirmed both in vitro and in vivo. Surface modification of the nanoparticles with the VHPK peptide ensured its capability to specifically target inflammatory endothelial cells and alleviate atherosclerotic plaque accumulation. In the ApoE − / − atherosclerotic mouse model, both colchicine and VHPK-PLGA@COL treatment significantly decreased the plaque area and enhanced plaque stability by blocking the NF-κB/NLRP3 pathways, while VHPK-PLGA@COL exhibited enhanced therapeutic effects due to its unique ability to target inflammatory endothelial cells without obvious long-term safety concerns. In summary, VHPK-PLGA@COL has the potential to overcome the key translational barriers of colchicine and open new avenues to repurpose this drug for anti-atherosclerotic therapy.
- 30 November 2023
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 21 (1) , 1-23
Open AccessColchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells
Atherosclerosis, a chronic inflammatory disease characterized by arterial plaque formation, is one of the most prominent causes of cardiovascular diseases. However, the current treatments often do not adequately compromise the chronic inflammation-mediated plaque accumulation and the disease progression. Therefore, a new and effective strategy that blocks atherosclerosis-associated inflammation is urgently needed to further reduce the risk. Colchicine, a potent anti-inflammatory medication, has shown great potential in the treatment of atherosclerosis, but its adverse effects have hampered its clinical application. Herein, we developed a novel delivery nanosystem encapsulated with colchicine (VHPK-PLGA@COL), which exhibited improved biosafety and sustained drug release along with the gradual degradation of PLGA and PEG as confirmed both in vitro and in vivo. Surface modification of the nanoparticles with the VHPK peptide ensured its capability to specifically target inflammatory endothelial cells and alleviate atherosclerotic plaque accumulation. In the ApoE − / − atherosclerotic mouse model, both colchicine and VHPK-PLGA@COL treatment significantly decreased the plaque area and enhanced plaque stability by blocking the NF-κB/NLRP3 pathways, while VHPK-PLGA@COL exhibited enhanced therapeutic effects due to its unique ability to target inflammatory endothelial cells without obvious long-term safety concerns. In summary, VHPK-PLGA@COL has the potential to overcome the key translational barriers of colchicine and open new avenues to repurpose this drug for anti-atherosclerotic therapy.
- Top Cited PapersOpen Access
- 30 June 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-17
Inhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviates atherosclerosis through the modulation of M1 polarization
Background: Inflammation and immune dysfunction with classically activated macrophages(M1) infiltration are important mechanisms in the progression of atherosclerosis (AS). Dynamin-related protein 1 (DRP1)-dependent mitochondrial fission is a novel target for alleviating inflammatory diseases. This study aimed to investigate the effects of DRP1 inhibitor Mdivi-1 on AS.Methods: ApoE−/−mice were fed with a high-fat diet supplemented with or without Mdivi-1. RAW264.7 cells were stimulated by ox-LDL, pretreated with or without MCC950, Mito-TEMPO, or Mdivi-1. The burden of plaques and foam cell formation were determined using ORO staining. The blood lipid profles and inflammatory cytokines in serum were detected by commercial kits and ELISA, respectively. The mRNA expression of macrophage polarization markers, activation of NLRP3 and the phosphorylation state of DRP1 were detected. Mitochondrial reactive oxygen species (mito-ROS), mitochondrial staining, ATP level and mitochondrial membrane potential were detected by mito-SOX, MitoTracker, ATP determination kit and JC-1 staining, respectively.Results: In vivo, Mdivi-1 reduced the plaque areas, M1 polarization, NLRP3 activation and DRP1 phosphorylation at Ser616. In vitro, oxidized low-density lipoprotein (ox-LDL) triggered M1 polarization, NLRP3 activation and abnormal accumulation of mito-ROS. MCC950 and Mito-TEMPO suppressed M1 polarization mediated foam cell formation. Mito-TEMPO significantly inhibited NLRP3 activation. In addition, Mdivi-1 reduced foam cells by inhibiting M1 polarization. The possible mechanisms responsible for the anti-atherosclerotic effects of Mdivi-1 on reducing M1 polarization were associated with suppressing mito-ROS/NLRP3 pathway by inhibiting DRP1 mediated mitochondrial fission. In vitro,similar results were observed by DRP1 knockdown.Conclusion: Inhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviated atherogenesis via suppressing mito-ROS/NLRP3-mediated M1 polarization, indicating DRP1-dependent mitochondrial fission as a potential therapeutic target for AS.
- 30 June 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-17
Top Cited PapersOpen AccessInhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviates atherosclerosis through the modulation of M1 polarization
Background: Inflammation and immune dysfunction with classically activated macrophages(M1) infiltration are important mechanisms in the progression of atherosclerosis (AS). Dynamin-related protein 1 (DRP1)-dependent mitochondrial fission is a novel target for alleviating inflammatory diseases. This study aimed to investigate the effects of DRP1 inhibitor Mdivi-1 on AS.Methods: ApoE−/−mice were fed with a high-fat diet supplemented with or without Mdivi-1. RAW264.7 cells were stimulated by ox-LDL, pretreated with or without MCC950, Mito-TEMPO, or Mdivi-1. The burden of plaques and foam cell formation were determined using ORO staining. The blood lipid profles and inflammatory cytokines in serum were detected by commercial kits and ELISA, respectively. The mRNA expression of macrophage polarization markers, activation of NLRP3 and the phosphorylation state of DRP1 were detected. Mitochondrial reactive oxygen species (mito-ROS), mitochondrial staining, ATP level and mitochondrial membrane potential were detected by mito-SOX, MitoTracker, ATP determination kit and JC-1 staining, respectively.Results: In vivo, Mdivi-1 reduced the plaque areas, M1 polarization, NLRP3 activation and DRP1 phosphorylation at Ser616. In vitro, oxidized low-density lipoprotein (ox-LDL) triggered M1 polarization, NLRP3 activation and abnormal accumulation of mito-ROS. MCC950 and Mito-TEMPO suppressed M1 polarization mediated foam cell formation. Mito-TEMPO significantly inhibited NLRP3 activation. In addition, Mdivi-1 reduced foam cells by inhibiting M1 polarization. The possible mechanisms responsible for the anti-atherosclerotic effects of Mdivi-1 on reducing M1 polarization were associated with suppressing mito-ROS/NLRP3 pathway by inhibiting DRP1 mediated mitochondrial fission. In vitro,similar results were observed by DRP1 knockdown.Conclusion: Inhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviated atherogenesis via suppressing mito-ROS/NLRP3-mediated M1 polarization, indicating DRP1-dependent mitochondrial fission as a potential therapeutic target for AS.
- Open Access
- 14 April 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 789331
SS31 Ameliorates Oxidative Stress via the Restoration of Autophagic Flux to Protect Aged Mice From Hind Limb Ischemia
Background: Oxidative stress and impaired autophagic flux play important roles in the development of peripheral artery disease (PAD). SS31 is considered an important antioxidant peptide and autophagy regulator. We aimed to investigate the role of SS31 in PAD myopathy and its possible mechanism both in vivo and in vitro.Methods: A hind limb ischemia (HLI) model was established with old C57BL/6 (14-month-old) mice. Mice in the SS31 group were intraperitoneally injected with SS31 (3 mg/kg) for 4 weeks. We examined skeletal muscle function and histomorphology, autophagy-related protein levels and reactive oxygen species (ROS) content. For the in vitro experiments, after C2C12 myotubes were treated with CoCl2, SS31, and chloroquine (CQ) or rapamycin (RAPA), we measured ROS content, autophagy-related protein levels and antioxidant enzyme expression.Results: SS31 treatment effectively enhanced the recovery of skeletal muscle function, alleviated skeletal muscle injury and suppressed mitochondrial ROS production in ischemic limbs. SS31 reduced apoptosis and oxidative stress, and SS31 restored impaired autophagic flux by inhibiting the AKT-mTOR pathway. In vitro studies showed that SS31 restored autophagic flux and improved oxidative stress in C2C12 cells. Moreover, phosphorylated AKT (p-AKT) and phosphorylated mTOR (p-mTOR) levels were reduced.Conclusion: These experiments indicated that SS31 can inhibit oxidative stress by restoring autophagic flux to reverse hypoxia-induced injury in vivo and in vitro.
- 14 April 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 789331
Open AccessSS31 Ameliorates Oxidative Stress via the Restoration of Autophagic Flux to Protect Aged Mice From Hind Limb Ischemia
Background: Oxidative stress and impaired autophagic flux play important roles in the development of peripheral artery disease (PAD). SS31 is considered an important antioxidant peptide and autophagy regulator. We aimed to investigate the role of SS31 in PAD myopathy and its possible mechanism both in vivo and in vitro.Methods: A hind limb ischemia (HLI) model was established with old C57BL/6 (14-month-old) mice. Mice in the SS31 group were intraperitoneally injected with SS31 (3 mg/kg) for 4 weeks. We examined skeletal muscle function and histomorphology, autophagy-related protein levels and reactive oxygen species (ROS) content. For the in vitro experiments, after C2C12 myotubes were treated with CoCl2, SS31, and chloroquine (CQ) or rapamycin (RAPA), we measured ROS content, autophagy-related protein levels and antioxidant enzyme expression.Results: SS31 treatment effectively enhanced the recovery of skeletal muscle function, alleviated skeletal muscle injury and suppressed mitochondrial ROS production in ischemic limbs. SS31 reduced apoptosis and oxidative stress, and SS31 restored impaired autophagic flux by inhibiting the AKT-mTOR pathway. In vitro studies showed that SS31 restored autophagic flux and improved oxidative stress in C2C12 cells. Moreover, phosphorylated AKT (p-AKT) and phosphorylated mTOR (p-mTOR) levels were reduced.Conclusion: These experiments indicated that SS31 can inhibit oxidative stress by restoring autophagic flux to reverse hypoxia-induced injury in vivo and in vitro.
- Open Access
- 1 October 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (10) , 10542-10555
A systematic review and meta-analysis of catheter ablation for atrial fibrillation
A systematic review and meta-analysis of catheter ablation for atrial fibrillation Peng Wang, Wuyang He, Chunqiu Li, Tingting Xiang, Qiaoyun Yang, Qingwei Chen
- 1 October 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (10) , 10542-10555
Open AccessA systematic review and meta-analysis of catheter ablation for atrial fibrillation
A systematic review and meta-analysis of catheter ablation for atrial fibrillation Peng Wang, Wuyang He, Chunqiu Li, Tingting Xiang, Qiaoyun Yang, Qingwei Chen
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 12
Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study
Studies have shown that dipeptidyl peptidase-4 (DDP-4) inhibitors have anti-atherosclerotic effects. However, in the PROLOGUE study, sitagliptin failed to slow the progression of carotid intima-media thickness (CIMT) relative to conventional therapy. We conducted a post hoc analysis of the PROLOGUE study and compared the effects of sitagliptin and conventional therapy on changes in CIMT in subgroups with or without hyperuricemia. The PROLOGUE study was a randomized controlled trial of 442 patients with type 2 diabetes mellitus (T2DM). Patients were randomized to receive sitagliptin added therapy or conventional therapy. Based on the serum uric acid levels of all study populations in the PROLOGUE study, we divided them into hyperuricemia subgroup (n = 104) and non-hyperuricemia subgroup (n = 331). The primary outcome was changed in carotid intima-media thickness (CIMT) parameters compared with baseline during the 24 months treatment period. In the hyperuricemia subgroup, compared with the conventional therapy group, the changes in the mean internal carotid artery (ICA)-IMT and max ICA-IMT at 24 months were significantly lower in the sitagliptin group [−0.233 mm, 95% confidence interval (CI) (−0.419 to 0.046), p = 0.015 and −0.325 mm, 95% CI (−0.583 to −0.068), p = 0.014], although there was no significant difference in the common carotid artery CIMT. The results of our analysis indicated that sitagliptin attenuated the progression of CIMT than conventional therapy in T2DM and hyperuricemia patients.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 12
Open AccessSitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study
Studies have shown that dipeptidyl peptidase-4 (DDP-4) inhibitors have anti-atherosclerotic effects. However, in the PROLOGUE study, sitagliptin failed to slow the progression of carotid intima-media thickness (CIMT) relative to conventional therapy. We conducted a post hoc analysis of the PROLOGUE study and compared the effects of sitagliptin and conventional therapy on changes in CIMT in subgroups with or without hyperuricemia. The PROLOGUE study was a randomized controlled trial of 442 patients with type 2 diabetes mellitus (T2DM). Patients were randomized to receive sitagliptin added therapy or conventional therapy. Based on the serum uric acid levels of all study populations in the PROLOGUE study, we divided them into hyperuricemia subgroup (n = 104) and non-hyperuricemia subgroup (n = 331). The primary outcome was changed in carotid intima-media thickness (CIMT) parameters compared with baseline during the 24 months treatment period. In the hyperuricemia subgroup, compared with the conventional therapy group, the changes in the mean internal carotid artery (ICA)-IMT and max ICA-IMT at 24 months were significantly lower in the sitagliptin group [−0.233 mm, 95% confidence interval (CI) (−0.419 to 0.046), p = 0.015 and −0.325 mm, 95% CI (−0.583 to −0.068), p = 0.014], although there was no significant difference in the common carotid artery CIMT. The results of our analysis indicated that sitagliptin attenuated the progression of CIMT than conventional therapy in T2DM and hyperuricemia patients.
- 17 November 2020
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 14 (16) , 1513-1520
Association of Fibrinogen/Albumin Ratio and Coronary Collateral Circulation in Stable Coronary Artery Disease Patients
Aim: To investigate whether fibrinogen/albumin ratio (FAR) has an association with the coronary collateral circulation (CCC) in patients with stable coronary artery disease. Materials & methods: A ...
- 17 November 2020
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 14 (16) , 1513-1520
Association of Fibrinogen/Albumin Ratio and Coronary Collateral Circulation in Stable Coronary Artery Disease Patients
Aim: To investigate whether fibrinogen/albumin ratio (FAR) has an association with the coronary collateral circulation (CCC) in patients with stable coronary artery disease. Materials & methods: A ...